[The epigenetic alteration and the effect of HDAC inhibitors in multiple myeloma].
Epigenetic abnormalities are central players in the disruption of common cancer pathway, and epigenetic aberrations have also been shown to play an important role in development of multiple myeloma. DNA methylation, histone modifications contribute to the pathogenesis of multiple myeloma. Understanding of epigenetic abnormalities in myeloma leads to development of novel drugs such as histone deacetylase inhibitors (HDACi). Here I will discuss about common epigenetic mechanisms (aberrant DNA methylation, histone modifications), the epigenetic aberrations in myeloma and clinical development of novel drug HDACi.